Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0003320,
umls-concept:C0011065,
umls-concept:C0012634,
umls-concept:C0019682,
umls-concept:C0032143,
umls-concept:C0035647,
umls-concept:C0042971,
umls-concept:C0085862,
umls-concept:C0205210,
umls-concept:C0220901,
umls-concept:C1299583,
umls-concept:C1549571,
umls-concept:C1608386,
umls-concept:C2347946
|
pubmed:issue |
3
|
pubmed:dateCreated |
1992-10-6
|
pubmed:abstractText |
Tissue-type plasminogen activator, von Willebrand factor, and plasminogen-activator inhibitor type 1 plasma levels were measured at first consultation in 85 consecutive patients infected with human immunodeficiency virus. Patients were assigned to three groups according to clinical status: mild disease group, intermediate group, and acquired immunodeficiency syndrome group. Significant differences were found in von Willebrand factor, tissue-type plasminogen activator, and plasminogen-activator inhibitor type 1 plasma levels among the three groups: severe clinical status was associated with higher von Willebrand factor, tissue-type plasminogen activator, and plasminogen-activator inhibitor type 1 plasma levels. Significant correlations were found among these three parameters, such known biologic prognostic indicators of human immunodeficiency virus infection as IgA, anti-p24 antibodies, p24 antigenemia, CD4+ lymphocytes, beta 2-microglobulin, and the clinical status. The prognostic relevance of plasma von Willebrand factor and tissue-type plasminogen activator levels at the time of entry into the study was then investigated in a cohort of 65 of the 85 patients who had follow-up during a median period of 22 months. The median survival time for all patients was 39 months after the first consultation. A plasma von Willebrand factor level greater than 200% of the control value had a positive predictive value of 86% for determining nonsurvivors; the median survival time for such patients was 9 months after the first consultation. A positive predictive value of 100% in recognizing nonsurvivors was found for tissue-type plasminogen factor plasma levels greater than 20 ng/ml; the median survival time for these patients was 2 months after the first consultation.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0022-2143
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
120
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
411-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1517688-Adolescent,
pubmed-meshheading:1517688-Adult,
pubmed-meshheading:1517688-Aged,
pubmed-meshheading:1517688-Cohort Studies,
pubmed-meshheading:1517688-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:1517688-Female,
pubmed-meshheading:1517688-HIV Infections,
pubmed-meshheading:1517688-HIV-1,
pubmed-meshheading:1517688-Humans,
pubmed-meshheading:1517688-Male,
pubmed-meshheading:1517688-Middle Aged,
pubmed-meshheading:1517688-Plasminogen Inactivators,
pubmed-meshheading:1517688-Prognosis,
pubmed-meshheading:1517688-Survival Analysis,
pubmed-meshheading:1517688-Tissue Plasminogen Activator,
pubmed-meshheading:1517688-von Willebrand Factor
|
pubmed:year |
1992
|
pubmed:articleTitle |
von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator.
|
pubmed:affiliation |
Department of Hematology and Immunology, University Hospital, Nîmes, France.
|
pubmed:publicationType |
Journal Article
|